Western diamondback rattlesnake venom components (C. atrox venom)

Western diamondback rattlesnake (Crotalus atrox) venom components consist of a diverse array of enzymes and non-enzymatic proteins that facilitate prey immobilization and digestion (Source: UniProt). The most significant components include snake venom metalloproteinases (SVMPs), which cause hemorrhage and tissue degradation, and phospholipases A2 (PLA2), which contribute to inflammation and cell membrane disruption (Source: PubMed, PMID: 31261704). Other constituents such as serine proteases and C-type lectins interfere with the coagulation cascade, leading to venom-induced consumptive coagulopathy (Source: Toxins Journal). In medical practice, these components are the primary targets of polyvalent antivenoms like CroFab and Anavip, which employ antibody fragments to sequester and neutralize the toxins (Source: FDA). Beyond their role in envenomation, specific components are studied for their potential as pharmacological leads in treating thrombosis and other vascular conditions. The complexity of the venom mixture presents a challenge for targeted therapy, as multiple distinct protein families must be neutralized simultaneously to prevent systemic toxicity.

Other names

Crotalus atrox venom proteinsWestern diamondback rattlesnake toxinsC. atrox venom

The primary mechanism of action for drugs targeting these components involves the use of antivenom antibodies that bind to and neutralize the enzymatic and toxic activities of the venom proteins (Source: FDA). Experimental small-molecule inhibitors like varespladib target specific enzymes such as phospholipase A2 to prevent membrane damage and inflammation (Source: PubMed, PMID: 32824345).